Inflammation, Immunity, and Cancer

Rajesh Singh [1] and Manoj Kumar Mishra [2] and Himanshu Aggarwal [3] 1, Morehouse School of Medicine, Atlanta, GA, USA, msm.edu 2, Alabama State University, Montgomery, AL, USA, alasu.edu 3, University of Alabama at Birmingham, Birmingham, AL, USA, uab.edu Received Sep 17, 2017; Accepted Sep 17, 2017 This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Another paper discusses osteopontin (OPN) appears to be a key determinant of the crosstalk between cancer cells and the host microenvironment, which in turn modulates immune evasion and describe the role of systemic, tumor-derived and stroma-derived OPN, highlighting its pivotal role at the crossroads of inflammation and tumor progression. In order to enhance immunity against cancer cells, genes elevating oncoimmunity have been engineered within the oncolytic virus. [...]a genetically engineered oncolytic virus with mAbs can be generated for advancement treatment in HCC models.